Company intelligence / Profile preview

EPD Biotherapeutics

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Programs are preclinical and focused on targeted degradation of undruggable proteins (e.g., SOX2) using engineered protein degrader platforms, aiming to address critical unmet needs in oncology and other disorders

Therapeutic areas: OncologyNeurologyRare DiseasesImmunology
Modalities: Engineered protein degraderProteolysis-targeting chimera therapyNanobody therapyBiologic
Industry: Biotech

Partnerships

Merger and partnership with Genexine

Beyond the preview

Go deeper on EPD Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPD Biotherapeutics.

Explore the full profile